Mgr. Hana Pálová, Ph.D.
Junior researcher, Ondřej Slabý Research Group
office: bldg. E35/225
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 6295 |
---|---|
e‑mail: |
Inactive employment status
Total number of publications: 46
2024
-
Dataset of DNA methylation profiles of 189 pediatric central nervous system, soft tissue, and bone tumors
Data in Brief, year: 2024, volume: 55, edition: August 2024, DOI
-
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
International journal of cancer, year: 2024, volume: 155, edition: 8, DOI
-
Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome
NPJ PRECISION ONCOLOGY, year: 2024, volume: 8, edition: 1, DOI
2023
-
Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.
Year: 2023, type: Conference abstract
-
Risk factors for tumors or leukemia development in the first two years of life
Biomedical Papers, Olomouc: Palacky University, year: 2023, volume: 167, edition: 2, DOI
-
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Scientific reports, year: 2023, volume: 13, edition: 1, DOI
-
Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors
Scientific Reports, year: 2023, volume: 13, edition: 1, DOI
-
Two sisters with cardiac-urogenital syndrome secondary to pathogenic splicing variant in the MYRF gene with unaffected parents: A case of gonadal mosaicism?
MOLECULAR GENETICS & GENOMIC MEDICINE, year: 2023, volume: 11, edition: 5, DOI
2022
-
Achalasia and acromegaly: co-incidence of these diseases or a new syndrome?
Biomedical Papers, year: 2022, volume: 166, edition: 2, DOI
-
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JCO PRECISION ONCOLOGY, year: 2022, volume: 6, edition: June 2022, DOI